Home > News > AlphaRx Reports Fiscal 2006 Year End Results
December 21st, 2006
AlphaRx Reports Fiscal 2006 Year End Results
Abstract:
"We are very pleased with the progress we have made in 2006, solidifying our R&D resources in the nanoparticle drug delivery platform, which has resulted in the recent signing of a Feasibility and Option Agreement with a global specialty pharmaceutical company for 3 drug products," stated Michael Lee, President and CEO. "We have also made significant progress this year in executing our strategy of building corporate partnerships and a strong product pipeline for long term growth. In 2007, we intend to focus on advancing our infectious diseases program into human clinical trials, and the pursuit of additional corporate partnerships for product commercialization and development."
Source:
marketwire.com
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Human Interest/Art
Drawing data in nanometer scale September 30th, 2022
Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022
Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021
JEOL Announces 2020 Microscopy Image Grand Prize Winners January 7th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||